Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11169978 | 0.86 | MAPT (0.45) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL27360925 | 0.85 | MAPT (0.45) | MAPTGAAALDH1A1HTTLMNA | |
| SCHEMBL11175518 | 0.83 | RAPGEF4 (0.41) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| Hydrochloric Acid SCHEMBL11171999 | 0.81 | RAPGEF4 (0.40) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL24635646 | 0.81 | GABRA1 (0.33) | MAPTGAAALDH1A1KMT2ACYP3A4 | |
| SCHEMBL7026512 | 0.80 | KMT2A (0.45) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL24635660 | 0.77 | MAPT (0.44) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL10393919 | 0.77 | KEAP1 (0.48) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL11169745 | 0.76 | MAPT (0.43) | KEAP1NFE2L2RAPGEF4MAPTGAA | |
| SCHEMBL12976027 | 0.76 | KEAP1 (0.44) | KEAP1NFE2L2RAPGEF4MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228479-A1 | PROCESS FOR SYNTHESIZING 2-BROMOLYSERGIC ACID DIETHYLAMIDE VIA CONTROLLED BROMINATION OF LYSERGIC ACID | CERUVIA LIFESCIENCES LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2022226408-A1 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228479-A1 | PROCESS FOR SYNTHESIZING 2-BROMOLYSERGIC ACID DIETHYLAMIDE VIA CONTROLLED BROMINATION OF LYSERGIC ACID | LIPA, NAAA, BRS3 | KEAP1 4056/4885NFE2L2 3356/4885RAPGEF4 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.